New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
11:50 EDTEXELExelixis announces availability of COMETRIQ in the U.S.
Exelixis announced the commercial availability of COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid cancer. The U.S. FDA approved COMETRIQ on November 29, 2012. COMETRIQ is being distributed exclusively through Diplomat Specialty Pharmacy in the U.S.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
09:22 EDTEXELOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quarter, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.
05:22 EDTEXELExelixis reports phase 3 pivotal trial of cobimetinib met secondary endpoint
Subscribe for More Information
September 25, 2015
18:49 EDTEXELExelixis up 16% after Phase 3 trial of cabozantinib met primary endpoint
In after-hours trading, shares are up 16% to $6.86.
18:16 EDTEXELExelixis says Phase 3 trial of cabozantinib met primary endpoint
Exelixis announced positive results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with renal cell carcinoma who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor. In July 2015, Exelixis disclosed that the trial met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients in the cabozantinib arm. Principal investigator Toni K. Choueiri, M.D. will present detailed data from the late-breaking METEOR abstract on Saturday, September 26, during the Presidential Session I at the European Cancer Congress 2015, which is being held September 25-29 in Vienna. The METEOR data and an accompanying editorial were also published today in The New England Journal of Medicine.
12:47 EDTEXELExelixis management to meet with William Blair
Meetings to be held in Europe on September 29-30 hosted by William Blair.
07:42 EDTEXELExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTEXELEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 23, 2015
07:18 EDTEXELExelixis to hold a webcast
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use